

FOCUSED

CGT Manufacturing



Enable.
Enhance.
Empower.



**COLLABORATIVE
PROJECT MANAGEMENT**



**ADVANCED TECH: iPSCs,
LVV & IMMUNOTHERAPIES**



**MANUFACTURING
EXPERTISE**

OmniaBio will be Canada's largest commercial-scale manufacturing facility for cell and gene therapies. As a CCRM subsidiary, OmniaBio Inc. will benefit from an ecosystem built over a decade.

The work carried out at OmniaBio will advance pioneering medicine with the potential to cure, not just treat, many forms of disease.

OmniaBio will be the anchor tenant of a new biomanufacturing campus located in Hamilton, Ontario, less than a one-hour drive from the U.S. border.

By providing commercial-scale manufacturing, OmniaBio will complete CCRM's continuum of process development, clinical and commercial capabilities.

[omniabio.com](https://www.omniabio.com)
CDMO@omniabio.com

Powered by



CATALYZING ADVANCEMENTS IN CGT MANUFACTURING



Flexible Operations:

Ranging from conventional full-service to customized hoteling, offering clients greater control.

Facility Design:

New, flexible build, amenable to advancements in manufacturing technology and not saddled with legacy infrastructure designed for pharmaceutical products.

McMaster Innovation Park Campus:

Will include integrated services, suppliers and incubators; a nucleus of synergies and opportunities for clients.

Next Generation Technologies:

Fully closed platforms for culture intensification and reduction in COGS.

AN ESTABLISHED FOUNDATION AND REPUTATION IN CGT



The Team:

CCRM's highly qualified personnel are focused on business, regulatory and IP services, alongside advanced manufacturing and process development, ensuring ongoing access to state-of-the-art platform advances for auto, allo and viral vectors.

Infrastructure:

40,000 sq ft of process development and Phase I/II GMP-compliant manufacturing with a large inventory of equipment spanning key technology platforms.

Training:

CCRM and CellCAN have created an advanced training institute (CATTI) to offer virtual and in-person GMP workforce training.

Partnerships:

Extensive engagement of technology partners and 300+ academic and industry organizations, globally; plus deep industry knowledge.



Site 1: 2024



~80,000 sq ft



15,000 sq ft lab
(PD, MSAT, QC)



15 clean rooms



iPSC line creation and editing, immunotherapy and lentiviral vector platforms.

Site 2: 2025-6



~315,000 sq ft



45,000 sq ft lab
(PD, MSAT, QC)



32 clean rooms



iPSC line creation and editing, immunotherapy and lentiviral vector platforms.

